Enanta Pharmaceuticals (ENTA) Operating Leases (2019 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Operating Leases came in at $52.8 million in Q1 2026, down 6.65% YoY from $56.5 million in Q1 2025, and down 1.87% on a QoQ basis from $53.8 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) Operating Leases (2019 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 8 years of Operating Leases data on file, last reported at $52.8 million in Q1 2026.
- Quarterly Operating Leases fell 6.65% year-over-year to $52.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.8 million (down 6.65% YoY) and the FY2025 annual result came in at $54.8 million, up 1.51% from the prior year.
- Operating Leases eased to $52.8 million in Q1 2026, from $53.8 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $56.5 million in Q1 2025 to a low of $15.1 million in Q1 2022.
- A 5-year average of $37.9 million and a median of $43.4 million in 2024 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases surged 1886.86% — and 2026, when it dropped 6.65%.
- Tracing ENTA's Operating Leases over 5 years: stood at $21.9 million in 2022, then retreated by 6.11% to $20.5 million in 2023, then soared by 175.06% to $56.5 million in 2024, then retreated by 4.73% to $53.8 million in 2025, then dropped by 1.87% to $52.8 million in 2026.
- The last three Operating Leases figures came in at $52.8 million (Q1 2026), $53.8 million (Q4 2025), and $54.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.75 Mn |
| Mar 31, 2026 | 52.78 Mn |
| Dec 31, 2025 | 53.78 Mn |
| Sep 30, 2025 | 54.76 Mn |
| Jun 30, 2025 | 55.66 Mn |
| Mar 31, 2025 | 56.54 Mn |
| Dec 31, 2024 | 56.45 Mn |
| Sep 30, 2024 | 53.94 Mn |
| Jun 30, 2024 | 48.14 Mn |
| Mar 31, 2024 | 43.41 Mn |
| Dec 31, 2023 | 20.52 Mn |
| Sep 30, 2023 | 21.24 Mn |
| Jun 30, 2023 | 22.33 Mn |
| Mar 31, 2023 | 23.07 Mn |
| Dec 31, 2022 | 21.86 Mn |
| Sep 30, 2022 | 22.37 Mn |
| Jun 30, 2022 | 22.21 Mn |
| Mar 31, 2022 | 15.12 Mn |
| Dec 31, 2021 | 15.96 Mn |
| Sep 30, 2021 | 1.13 Mn |